Head of Commercial
RetinAI Medical
Head of Commercial
RetinAI Medical
AI-driven ophthalmology imaging data platform
RetinAI Medical · Bern, Switzerland (Hybrid) · Full-time · Posted 2026-07-02
Workplace: hybrid
Department: Marketing
Ikerian AG (formerly RetinAI, now part of Essilor Luxottica) is a fast-growing software company headquartered in Bern, Switzerland. Our mission is to enable the right decisions sooner in healthcare, through transformative AI & data management solutions to better understand patients and diseases. Join our diverse team of entrepreneurs, developers, researchers, and commercial experts who are collectively shaping the future of healthcare and eyecare.
The Head of Commercial is the head of Ikerian’s market footprint and global revenue growth. Your mission is to optimize a complex revenue mix spanning scalable clinical SaaS, bespoke research collaborations, and Data-Driven Intelligence solutions for the pharma and clinical segment. You will professionalize our commercial engine by ensuring operational excellence while bridging the gap between innovation and global demand. As a key leader within the company and the EssilorLuxottica ecosystem, you will orchestrate strategic partnerships and implement new commercial concepts across global distribution models to maximize corporate synergies.
Powered by Workable
AI-driven ophthalmology imaging data platform
RetinAI Discovery is an AI-powered, subscription-based data platform for ophthalmology and optometry that lets eye-care professionals, researchers and sponsors collect, harmonize, analyze and securely share imaging and other medical data (DICOM and proprietary formats). It uses AI to extract insights on disease progression and treatment outcomes, helping clinicians and trial teams make faster, data-driven decisions with capabilities for data collection, processing, visualization and global collaboration. It differentiates itself by focusing specifically on eye care, offering an end-to-end platform that handles diverse data formats and cross-institution collaboration, supported by its US subsidiary and strong investor backing. Its goal is to streamline data-driven clinical decisions and make ophthalmology trials more efficient, expanding within the Ikerian group and its connection to EssilorLuxottica.
Explore more opportunities at RetinAI Medical